Abbott Laboratories (ABT) Falls 9.27% for January 28

Equities Staff |

One of the S&P 500’s big losers for Thursday January 28 was Abbott Laboratories (ABT). The company’s stock fell 9.27% to $36.72 on volume of 19.66 million shares.

The stock opened the day at 38.41 and traded between a low of $36.00 and a high of $38.50. The stock finished the day down $3.75 per share. Abbott Laboratories has an average daily volume of 6.98 million and a total float of 1.49 billion shares. The 50-day SMA for Abbott Laboratories is $43.45 and its 200-day SMA is $45.44. The high for the stock over the last 52 weeks is $51.74 and the low is $39.00.

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is centered in Abbott Park, IL, and has 77,000 employees. Today’s trading day leaves the company with a market cap of $54.78 billion. The company has a P/S ratio of n/a, P/B ratio of 2.6, and a 24.4.

For a complete fundamental analysis analysis of Abbott Laboratories, check out’s Stock Valuation Analysis report for ABT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…